These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 35350032)
1. Microsatellite Instability Analysis and Its Prognostic Value in Invasive Nonampullary Duodenal Adenocarcinoma. Yang G; Tanaka T; Kinugasa H; Kanzaki H; Chen MX; Ichimura K; Nakagawa M; Jin ZS; Zheng RY; Yoshino T Oncology; 2022; 100(5):290-302. PubMed ID: 35350032 [TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma. Klose J; Lasitschka F; Horsch C; Strowitzki MJ; Bruckner T; Volz C; Schmidt T; Schneider M Scand J Gastroenterol; 2020 Mar; 55(3):321-329. PubMed ID: 32191146 [No Abstract] [Full Text] [Related]
3. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695 [TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F; Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808 [TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. Watari J; Mitani S; Ito C; Tozawa K; Tomita T; Oshima T; Fukui H; Kadowaki S; Natsume S; Senda Y; Tajika M; Hara K; Yatabe Y; Shimizu Y; Muro K; Morimoto T; Hirota S; Das KM; Miwa H Sci Rep; 2019 Jul; 9(1):10526. PubMed ID: 31324814 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884 [TBL] [Abstract][Full Text] [Related]
9. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. Giuffrida P; Arpa G; Grillo F; Klersy C; Sampietro G; Ardizzone S; Fociani P; Fiocca R; Latella G; Sessa F; D'Errico A; Malvi D; Mescoli C; Rugge M; Nesi G; Ferrero S; Furlan D; Poggioli G; Rizzello F; Macciomei MC; Santini D; Volta U; De Giorgio R; Caio G; Calabrò A; Ciacci C; D'Armiento M; Rizzo A; Solina G; Martino M; Tonelli F; Villanacci V; Cannizzaro R; Canzonieri V; Florena AM; Biancone L; Monteleone G; Caronna R; Ciardi A; Elli L; Caprioli F; Vecchi M; D'Incà R; Zingone F; D'Odorico A; Lenti MV; Oreggia B; Reggiani Bonetti L; Astegiano M; Biletta E; Cantoro L; Giannone AG; Orlandi A; Papi C; Perfetti V; Quaquarini E; Sandri G; Silano M; Usai P; Barresi V; Ciccocioppo R; Luinetti O; Pedrazzoli P; Pietrabissa A; Viglio A; Paulli M; Corazza GR; Solcia E; Vanoli A; Di Sabatino A Mod Pathol; 2020 Jul; 33(7):1398-1409. PubMed ID: 32066859 [TBL] [Abstract][Full Text] [Related]
11. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847 [TBL] [Abstract][Full Text] [Related]
12. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma. Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305 [TBL] [Abstract][Full Text] [Related]
14. Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy. Tural D; Akar E; Baytekin HF; Canoglu D; Yilmaz M; Tugcu V J BUON; 2021; 26(5):2117-2125. PubMed ID: 34761625 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors. Zhang Y; Jin J; Tang M; Li P; Zhou LN; Du YP; Chen MB Biomed Res Int; 2022; 2022():6743126. PubMed ID: 35707390 [TBL] [Abstract][Full Text] [Related]
16. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457 [TBL] [Abstract][Full Text] [Related]
17. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918 [TBL] [Abstract][Full Text] [Related]
18. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer]. Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814 [No Abstract] [Full Text] [Related]
19. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials. Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]